RFL
RafaelFNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that RFL now looks increasingly like a focused Trappsol Cyclo vehicle, with management explicitly prioritizing completion of the pivotal Phase 3 trial and an April 2026 MIT license that may support follow-on neurodegenerative optionality [#10-Q-2026-03-16][#8-K-2026-04-22].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash burn and clinical spending trends may force additional financing before full de-risking of the lead program.
Momentum
66
Value
41
Sentiment
9
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.20 · Bull $2.10 · Bear $0.70
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum66 · Δ7d -
Value41 · Δ7d -0.1
Sentiment9 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
66
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
9
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 65.6 / Value 41.1 / Sentiment 9.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$112.86M
Beta
0.68
Shares Out
52M
P/E (TTM) · Derived
-2.1
P/S (TTM)
63.89
P/FCF (TTM) · Derived
-3.27
Rev YoY
-50.6%
EPS YoY
-55.8%
Gross Margin
+74.4%
Op Margin
-3442.4%
Net Debt
-$52.08M
Current Ratio
3.16
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology